Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 March 2025, including: Pfizer tops pharma leaderboard; AstraZeneca buys into in vivo cell therapy; Almirall looks to dominate derma spectrum; Incyte’s HS contender looks approvable; and MSD’s Williams says pharma should shorten tech adoption cycles.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
This episode was produced using AI text-to-speech and voice emulation tools.
Stories mentioned in this episode:
- Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again
- AstraZeneca Buys Into In Vivo Cell Therapy Potential With EsoBiotec
- Almirall Looks To Dominate Across Derma Spectrum
- Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?
- MSD’s CIDO Williams: ‘We Must Shorten Technology Adoption Cycles’
